Bifogade filer
Chordate-Tidigarelagd-delarsrapport-Q3-21-EN.pdf
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Chordate Medical Holding AB (publ) ("Chordate" or "the Company") hereby announces that the Board has today decided to bring forward the company's report for Q3 2021 to give owners and stakeholders in the outstanding warrant TO7 the opportunity to view the quarterly report before trading in the option ends October 27, 2021, and before October 29, 2021, which is the last day for redemption of TO7. The report for the period July-September 2021 will be published on October 25 2021 instead of November 19 as previously communicated.
The company's financial calendar has been updated and can be found at https://www.chordate.com/en/investor-relations/financial-calendar/
This disclosure was submitted for publication, through the contact person below, on September 23rd, 2021, at 16:00 pm CET.
For more information, please contact:
Anders Weilandt
Managing Director
Cell: +46 733-874277, e-mail: anders.weilandt@chordate.com
The following documents can be retrieved from beQuoted
Chordate-Tidigarelagd-delarsrapport-Q3-21-EN.pdf
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more athttps://www.chordate.com/en/